Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase 3 Randomized Controlled Trial of Rondecabtagene Autoleucel , an Autologous, Dual-targeting CD19/CD20 CAR T-Cell Product Candidate, Vs. Investigator's Choice of CD19 CAR T-Cell Therapy in Patients With Relapsed or Refractory Large B-Cell Lymphoma in the Second-line Setting

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT07188558
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-25T22:28:18.397032+00:00
Published At
2026-03-04T00:00:00+00:00
Record Updated At
2026-03-04
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Large B-cell Lymphoma", "Lymphoma, B-Cell", "Relapsed Non-Hodgkin Lymphoma", "Refractory Non-Hodgkin Lymphoma", "Non-Hodgkin Lymphoma", "Non-Hodgkin Lymphoma Refractory/ Relapsed", "Diffuse Large B Cell Lymphoma (DLBCL)", "Diffuse Large B Cell Lymphoma Refractory", "Diffuse Large B Cell Lymphoma Relapsed"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2026-03-04"
protocolSection.identificationModule.nctId
"NCT07188558"
protocolSection.identificationModule.officialTitle
"A Phase 3 Randomized Controlled Trial of Rondecabtagene Autoleucel , an Autologous, Dual-targeting CD19/CD20 CAR T-Cell Product Candidate, Vs. Investigator\u0027s Choice of CD19 CAR T-Cell Therapy in Patients With Relapsed or Refractory Large B-Cell Lymphoma in the Second-line Setting"
protocolSection.statusModule.overallStatus
"RECRUITING"
protocolSection.designModule.phases
["PHASE3"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • Large B-cell Lymphoma (protocolSection.conditionsModule.conditions)
  • Lymphoma, B-Cell (protocolSection.conditionsModule.conditions)
  • Relapsed Non-Hodgkin Lymphoma (protocolSection.conditionsModule.conditions)
  • Refractory Non-Hodgkin Lymphoma (protocolSection.conditionsModule.conditions)
  • Non-Hodgkin Lymphoma (protocolSection.conditionsModule.conditions)
  • Non-Hodgkin Lymphoma Refractory/ Relapsed (protocolSection.conditionsModule.conditions)
  • Diffuse Large B Cell Lymphoma (DLBCL) (protocolSection.conditionsModule.conditions)
  • Diffuse Large B Cell Lymphoma Refractory (protocolSection.conditionsModule.conditions)
  • Diffuse Large B Cell Lymphoma Relapsed (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.